Mary Wilson
Well-known member
February 10, 2025
DOI: 10.1016/S1473-3099(25)00079-9
Luo Chen[SUP]a,b[/SUP] ∙ Yu Kaku[SUP]a[/SUP] ∙ Kaho Okumura[SUP]a,c[/SUP] ∙ Keiya Uriu[SUP]a[/SUP] ∙ Yukun Zhu[SUP]a[/SUP]on behalf of the The Genotype to Phenotype Japan (G2P-Japan) Consortium∙ Jumpei Ito[SUP]a,d,f[/SUP] ∙ Kei Sato[SUP]a,b,d,e,f,g,h,i[/SUP]
After the rapid spread of the SARS-CoV-2 JN.1 (BA.2.86.1.1) variant,[SUP]1[/SUP]several descendant lineages of JN.1, including KP.2 (JN.1.11.1.2),[SUP]2[/SUP] KP.3 (JN.1.11.1.3),[SUP]2[/SUP] and KP.3.1.1 (JN.1.11.1.3.1.1),[SUP]3[/SUP] have emerged and rapidly spread globally. Subsequently, XEC has become prevalent and currently accounts for nearly half of all infections, as of January, 2025.[SUP]4[/SUP] Thereafter, LP.8.1 (JN.1.11.1.1.1.3.8.1), a descendant lineage of KP.1.1.3 (JN.11.1.1.1.3), is starting to spread worldwide. LP.8.1 has acquired nine spike protein mutations compared with JN.1, and eight amino acid residues differ between the spike proteins of LP.8.1 and XEC (appendix p 18). Here, we estimate the relative effective reproduction number (R[SUB]e[/SUB]) of LP.8.1 with a Bayesian multinomial logistic model[SUP]1–4[/SUP] based on genome surveillance data from Canada, the USA, Japan, and Australia, where this variant has spread, as of December, 2024 (appendix p 18). Although the R[SUB]e[/SUB] of LP.8.1 is 1·067-fold higher than that of XEC in the USA, the difference between the R[SUB]e[/SUB] of LP.8.1 and XEC was relatively small in Japan (1·019-fold; appendix p 18). ...
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00079-9/fulltext
DOI: 10.1016/S1473-3099(25)00079-9
Luo Chen[SUP]a,b[/SUP] ∙ Yu Kaku[SUP]a[/SUP] ∙ Kaho Okumura[SUP]a,c[/SUP] ∙ Keiya Uriu[SUP]a[/SUP] ∙ Yukun Zhu[SUP]a[/SUP]on behalf of the The Genotype to Phenotype Japan (G2P-Japan) Consortium∙ Jumpei Ito[SUP]a,d,f[/SUP] ∙ Kei Sato[SUP]a,b,d,e,f,g,h,i[/SUP]
After the rapid spread of the SARS-CoV-2 JN.1 (BA.2.86.1.1) variant,[SUP]1[/SUP]several descendant lineages of JN.1, including KP.2 (JN.1.11.1.2),[SUP]2[/SUP] KP.3 (JN.1.11.1.3),[SUP]2[/SUP] and KP.3.1.1 (JN.1.11.1.3.1.1),[SUP]3[/SUP] have emerged and rapidly spread globally. Subsequently, XEC has become prevalent and currently accounts for nearly half of all infections, as of January, 2025.[SUP]4[/SUP] Thereafter, LP.8.1 (JN.1.11.1.1.1.3.8.1), a descendant lineage of KP.1.1.3 (JN.11.1.1.1.3), is starting to spread worldwide. LP.8.1 has acquired nine spike protein mutations compared with JN.1, and eight amino acid residues differ between the spike proteins of LP.8.1 and XEC (appendix p 18). Here, we estimate the relative effective reproduction number (R[SUB]e[/SUB]) of LP.8.1 with a Bayesian multinomial logistic model[SUP]1–4[/SUP] based on genome surveillance data from Canada, the USA, Japan, and Australia, where this variant has spread, as of December, 2024 (appendix p 18). Although the R[SUB]e[/SUB] of LP.8.1 is 1·067-fold higher than that of XEC in the USA, the difference between the R[SUB]e[/SUB] of LP.8.1 and XEC was relatively small in Japan (1·019-fold; appendix p 18). ...
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00079-9/fulltext